Commentary

Video

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Author(s):

Natasha B Leighl, MD, BSc, MMSc
Conference|IASLC World Conference on Lung Cancer

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

Natasha B. Leighl, MD, BSc, MMSc, clinician investigator and member of the Cancer Clinical Research Unit (CCRU) at Princess Margaret Cancer Centre, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study (NCT05388669).

Related Videos
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
John Seymour, MBBS, FRACP, PhD
Related Content
Nancy U. Lin, MD. Dana-Farber Cancer Institute
September 13th 2024

DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ewa Kalinka, MD, PhD, of the Instytut Centrum Zdrowia Matki Polki-Klinika Onkologil
September 13th 2024

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Suresh Senan, MRCP, FRCR, PhD
September 13th 2024

Consolidation Durvalumab Shows Consistent Survival Benefit in LS-SCLC Regardless of Prior PCI and CRT Components

Glenwood Goss, MB, BCh, FCPSA, FRCPC
September 13th 2024

Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status